Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Laekna, Inc. ( (HK:2105) ) has provided an announcement.
Laekna, Inc. has begun recruiting participants and has dosed the first subject in a Phase I single ascending dose clinical trial of LAE103, an internally discovered monoclonal antibody targeting ActRIIB, in Australia. The randomized, double-blind, placebo-controlled study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered LAE103 in healthy overweight or obese volunteers, with topline data expected in the third quarter of 2026, marking a key early milestone in Laekna’s strategy to develop novel treatments for obesity, sarcopenia and heart failure and potentially strengthen its position in the cardiovascular and metabolic disease arena.
The most recent analyst rating on (HK:2105) stock is a Buy with a HK$24.16 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page.
More about Laekna, Inc.
Laekna, Inc. is a biotechnology company focused on developing innovative precision therapies for cardiovascular and metabolic diseases with high unmet medical needs, including obesity, sarcopenia and heart failure. The company is advancing a pipeline of internally discovered drug candidates, such as monoclonal antibodies, aimed at addressing these chronic and increasingly prevalent conditions in global healthcare markets.
Average Trading Volume: 3,208,134
Technical Sentiment Signal: Hold
Current Market Cap: HK$5.69B
For a thorough assessment of 2105 stock, go to TipRanks’ Stock Analysis page.